INTEGRA LIFESCIENCES HOLDINGS CORP
Close on Oct 19, 2026
- Market cap
- $1.05B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 29, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 29, 2026 | Before market open | $418.80M | $0.06 | $0.56 |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | Before market open | $391.90M | $-0.06 | $0.54 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | $434.90M | $-0.02 | $0.83 |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 30, 2025 | Before market open | $402.10M | $-0.07 | $0.54 |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 31, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 5, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 25, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 4, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 29, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 6, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 28, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Jul 29, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| adjusted earnings per sharenon-GAAP | full year 2026 | $2.40 to $2.50 | Maintained |
| adjusted EPSnon-GAAP | third quarter of 2026 | $0.53 to $0.61 | New |
| organic revenue growthnon-GAAP | full year 2026 | 0.8% to 3.3% growth | New |
| reported growthGAAP | third quarter of 2026 | 2% to 5.7% growth | New |
| organic growthnon-GAAP | third quarter of 2026 | 1.9% to 5.7% growth | New |
| reported revenue outlookGAAP | full year 2026 | $1.65B to $1.70B | New |
| reported revenuesGAAP | third quarter of 2026 | $410.00M to $425.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Integra Lifesciences filed with the SEC
Integra Announces Pricing of Senior Secured Notes
Regulation FD disclosure · EX-99.1 to Form 8-K
Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Integra LifeSciences Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Integra LifeSciences Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Integra LifeSciences Reports Fourth Quarter and Full-Year 2025
Results of operations · EX-99.1 to Form 8-K
Integra LifeSciences Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Integra LifeSciences Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Integra LifeSciences Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Integra LifeSciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides 2025 Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Integra LifeSciences Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Integra LifeSciences Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Integra LifeSciences Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Chris Ward (609) 772‐7736 [email protected] Media: Laurene Isip (609) 208‐8121 [email protected]
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Integra LifeSciences Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
ACQUISTION OF ACCLARENT, A LEADER IN ENT SURGICAL INTERVENTIONS DECEMBER 13, 2023 Exhibit 99.2
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Integra LifeSciences Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Integra LifeSciences Reports Second Quarter 2023 Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K